Alfa in Biological Technology
Navigation Links
Alfa in Biological Technology
Trial will also Support a Marketing Authorization Application in the European Union
HOUSTON, Jan. 17 /PRNewswire/ -- Agennix Incorporated announced today
that the U.S. Food and Drug Administration (FDA) has approved the design of
a single, pivotal, Phase 3 trial e...
... Early hemoglobin decline and survival prognosis in epoetin alfa studies (Abstract 9625) General Poster Session, Monday Jun...noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ. Important Safety Informati...
... 2010; - VYVANSE (lisdexamfetamine dimesylate) for use in the treatment of ADHD in children in Canada during 2010; and - Velaglucerase alfa for the treatment of Gaucher disease in the US and the EU in 2010. CASHFLOW AND LIQUIDITY Shire's robust balance sheet includes ...
...ollowing the end of treatment). About Albinterferon Alfa-2b (Albuferon) Albinterferon alfa-2b is a novel, longer-acting form of interferon alfa that was created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the hu...
...tment group. About Albinterferon Alfa-2b (Albuferon) Albinterferon alfa-2b is a novel, longer-acting form of interferon alfa that was created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the hu...
... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in t...
...olescents in the US in 2010; and - Velaglucerase alfa for the treatment of Gaucher disease in the US ...S development plan in due course. Velaglucerase alfa - Gaucher disease - Shire has completed enrolmen... program includes the evaluation of velaglucerase alfa in naive patients and patients previously treat...
...armaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesyla...
...nd marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious il...
...nd marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious il...
... by the FDA on January 23, 2008. - Velaglucerase alfa (GA-GCB) - Gaucher disease - A worldwide Phase 3 c...of JUVISTA(R) (Human TGF beta 3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization incl...he continuation of Phase 3 trials on velaglucerase alfa (GA-GCB); the development of the Women's Health fr...
...on and suicidal behavior, including suicidal ideation, suicidal attempts and completed suicides, have been reported in association with treatment with alfa interferons. Important Safety Information Regarding U.S. Labeling for PEGINTRON(TM) Alpha interferons, including PEGINTRON(TM) and INTRON(R) A, may ...
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP ) today announced results from the Phas...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
...impairment in depression. Velaglucerase alfa - for the treatment of Gaucher disease - On J... the rolling submission of a NDA for velaglucerase alfa to treat patients with Type 1 Gaucher diseas...mprovements in the primary endpoint. Velaglucerase alfa was also found to be well tolerated with no ...... Early hemoglobin decline and survival prognosis in epoetin alfa studies (Abstract 9625) General Poster Session, Monday Jun...noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ. Important Safety Informati...
Shire begins the year with a strong performance
...scents in the US in the fourth quarter of 2009; - DAYTRANA for the treatment of ADHD in adolescents in the US in 2010; - Velaglucerase alfa for the treatment of Gaucher disease in the US and the EU in 2010; and - VYVANSE for the treatment of ADHD, in ex-US and ex-EU regions star...Publication of Shire plc's Annual Report 2008
...the US, including VYVANSE, DAYTRANA, velaglucerase alfa (GA-GCB), SPD550, PLICERA, AMIGAL, AT2220 and META... in Canada; and - the launch of Velaglucerase alfa in the EU. This program of new product lau...d quarter of 2009. ERT Velaglucerase alfa (GA-GCB) - for the treatment of Gaucher disease ...... 2010; - VYVANSE (lisdexamfetamine dimesylate) for use in the treatment of ADHD in children in Canada during 2010; and - Velaglucerase alfa for the treatment of Gaucher disease in the US and the EU in 2010. CASHFLOW AND LIQUIDITY Shire's robust balance sheet includes ...
...ollowing the end of treatment). About Albinterferon Alfa-2b (Albuferon) Albinterferon alfa-2b is a novel, longer-acting form of interferon alfa that was created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the hu...
...tment group. About Albinterferon Alfa-2b (Albuferon) Albinterferon alfa-2b is a novel, longer-acting form of interferon alfa that was created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the hu...
EMD Serono Launches Landmark Patient Registry for Egg Freezing
... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in t...Shire's New Product Portfolio Delivers Strong Quarterly Performance
... - DAYTRANA(R) (methylphenidate transdermal system) for use in children in the EU in 2009 and adolescents in the US in 2010; and - Velaglucerase alfa for the treatment of Gaucher disease in the US and the EU in 2010. Update on Current Portfolio VYVANSE(R) (lisdexamfetamine dimesylate) - Attent...... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in t...
EMD Serono Named as a Top Employer by Science Magazine
... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in t...33rd ESMO Congress in Stockholm, 12-16 September 2008
...ptember 2008, 08:45 CEST) For patients suffering from chemotherapy-induced anaemia, adding intravenous iron to treatments with the drug darbepoietin alfa results in better haematologic response, and a faster improvement in the condition, US researcher Michael Auerbach reports. Patient seminar An est...Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A
...nd marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious il......olescents in the US in 2010; and - Velaglucerase alfa for the treatment of Gaucher disease in the US ...S development plan in due course. Velaglucerase alfa - Gaucher disease - Shire has completed enrolmen... program includes the evaluation of velaglucerase alfa in naive patients and patients previously treat...
Lilly Reports Solid Second-Quarter Results
...origin, Lilly) Strattera(R) (atomoxetine hydrochloride, Lilly) Symbyax(R) (olanzapine fluoxetine combination, or OFC, Lilly) Xigris(R) (drotrecogin alfa (activated), Lilly) Yentreve(R) (duloxetine hydrochloride, Lilly) Zyprexa(R) (olanzapine, Lilly) AIR(R) is a trademark of Alkermes, Inc. Eli ...Genzyme Reports Strong Second-Quarter Growth
...approval by the end of this year for alglucosidase alfa (Myozyme(R)) produced at the 2000L bioreactor scal...ng in October to discuss the BLA for alglucosidase alfa produced at the 2000L-scale, as required for all n...rly next year. Sales of Thyrogen(R) (thyrotropin alfa for injection) remained strong, increasing 34 perc...EMD Serono to Adopt Revised and Strengthened PhRMA Code
... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in t......armaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesyla...
Application for Listing of Shire Limited Ordinary Shares
...armaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF beta 3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesyla...CURE Magazine Announces Winner of 2008 Extraordinary Healer Award
...nd marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious il......nd marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious il...
Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
...armaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesyla...Publication of Supplementary Prospectus
...armaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesyla...Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
...rmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGF beta 3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylat...Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
...armaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesyla...Genzyme Reports Strong First-Quarter Growth
...in Pharmaceutical Inc. on worldwide product sales under a restructured agreement between the companies. -- Sales of Thyrogen(R) (thyrotropin alfa for injection) grew 28 percent in the first quarter to $33.8 million from $26.3 million, reflecting ongoing improvement in thyroid cancer dete...Lilly Reports Solid First-Quarter Results
...TM) (Lilly) Strattera(R) (atomoxetine hydrochloride, Lilly) Symbyax(R) (olanzapine fluoxetine combination, or OFC, Lilly) Xigris(R) (drotrecogin alfa (activated), Lilly) Yentreve(R) (duloxetine hydrochloride, Lilly) Zyprexa(R) (olanzapine, Lilly) -------------------------------------------- ...New Shire Holding Company Proposal
...rmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGF(BETA)3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylat...EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in t...Shire plc: IFRS Results for the Year Ending December 31, 2007
...R&D expenditure in 2007 was due to Phase 3(b) and Phase 4 studies to support new product launches; the continuation of Phase 3 trials on velaglucerase alfa (GA-GCB); the development of the Women's Health franchise and JUVISTA; the pre-clinical development of three HGT projects and the newly in-licensed pr...Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
...uvant breast cancer treatment in which darbepoetin alfa was administered to prevent anemia at target hemog...surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ. Impor...Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also ma......nd marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious il...
Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
... noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ. Important U.S. Safety Informat...Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recu...... by the FDA on January 23, 2008. - Velaglucerase alfa (GA-GCB) - Gaucher disease - A worldwide Phase 3 c...of JUVISTA(R) (Human TGF beta 3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization incl...he continuation of Phase 3 trials on velaglucerase alfa (GA-GCB); the development of the Women's Health fr...
Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing
...nd marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious il......on and suicidal behavior, including suicidal ideation, suicidal attempts and completed suicides, have been reported in association with treatment with alfa interferons. Important Safety Information Regarding U.S. Labeling for PEGINTRON(TM) Alpha interferons, including PEGINTRON(TM) and INTRON(R) A, may ...
Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
...ck KGaA in Darmstadt, Germany. EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). The company has strong market positions in neurodegenerative dis...Schering-Plough Completes Acquisition of Organon BioSciences
...g, sublingual psychopharmacologic agent for the treatment of patients with schizophrenia and acute mania bipolar disorder; * Corifollitropin alfa (from Organon), a new fertility hormone; * Golimumab, an anti-inflammatory for the treatment of rheumatoid arthritis, psoriatic arthritis and an...Other TagsCannabinoidCalanOther Contentsalimentaryalimentaryalkalinealkalinealkalinealkalinealkalinealkalinealkalinealkalinealkalineagentsagentsagentsagentsagentsagentsagentsagentsagentsalkylatingalkylatingallantoisallostericallostericallosteric
CaroteneCarisoprodolCardizemCardioquinCarboxyhemoglobinCarbolicCarbidopaCanrenoneCannabinoidCalprotectinCampylobacterCalcofluorCalculiCalan
(Date:11/26/2009)...er 26, 2009) Whitehead researchers have developed...inpoint specific genes and proteins used by pathog... most human cell cultures genes are present in two...m the mother. Gene inactivation by mutation is the...vated, the second copy usually remains active and ...
(Date:11/25/2009)...n,t have easy lives. In addition to mammalian immu...l enemies called bacteriophages, viruses that kill...till, bacteria and another class of microorganisms...onments such as deep-sea volcanic vents) manage ju...ilt-in defense system that helps protect them from...
(Date:11/25/2009)...y assistant professors recently received funding f...nue research beneficial to understanding the envir...topher Blackwood, assistant professor in the Depar...o support two separate research projects. , His ...r Communities and Functions from the Leaf to the L...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Kent State University professors focus research on the environment with grants totaling $890,000 2Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 1Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 2Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 3Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 4Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 5Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 6Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 7Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 8Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 9Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 10Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 11Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 12Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 13Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 14Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 15Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 16Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 17Sonic Innovations Named as CES Innovations 2010 Design and Engineering Award Honoree 6229 1Sonic Innovations Named as CES Innovations 2010 Design and Engineering Award Honoree 6229 2Sonic Innovations Named as CES Innovations 2010 Design and Engineering Award Honoree 6229 3Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 1Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 2Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 3Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 4Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 5Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 6Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 7Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 8Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 9Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 10Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 11Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6224 12(Date:11/27/2009)...ov. 27 Preventing disea...ortunately every year, new vaccines are being adde...ines boost immunity for the same period of time? A...eded to keep immunity strong? ,, In this mont...an Academy of Pediatrics, Michael Pichichero MD, D...
(Date:11/27/2009)...dented medical, economic burdens, study predicts ,...he number of people with diabetes in the United St... a new study predicts. , That would bring the t... disease, up from 23.7 million today. , , At the...tes will triple, the study also warns, rising from...
(Date:11/27/2009)...e new interactive anatomy education apps from Moda...health sciences learning opportunities for iPhone ...NC (Vocus) November 27, 2009 -- Modality, Inc. a...sion of Wolters Kluwer Health, today announced the...on the App Store. Clemente’s Anatomy, Rohen&...
(Date:11/26/2009)...heavy can lead to strains or worse , , T...nothing wrong with stuffing your turkey full to bu...g with your suitcase as you pack for holiday trips...8 in U.S. hospital emergency rooms, doctors, offic...ge-related injuries, such as muscle strains, pulls...
(Date:11/26/2009)...on Communications announces a highly effective and...rs struggling to make an economic recovery. , ...Flu fears is the type of challenge that could send...ding to Dr. David Benton, business growth expert a...stem – The Rfactor Intensive . “Fea...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Pharmacist Injects Cure for Ailing Businesses 2[0] Why Some Vaccines May Require A Booster[0] Diabetes Cases Expected to Double in 25 Years[0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store[2] Pack Right for the Holidays to Avoid the ER[1] Pharmacist Injects Cure for Ailing Businesses
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |